Perrigo Plc's Revenue in the fiscal year 2025 $ 4,252.50 millions
Perrigo Plc's Revenue in the fiscal year 2024 $ 4,372.70 millions
Perrigo Plc's Revenue in the fiscal year 2023 $ 4,655.40 millions
Perrigo Plc's Revenue in the fiscal year 2022 $ 4,451.40 millions
Perrigo Plc's Revenue in the fiscal year 2021 $ 4,138.70 millions
PRGO Revenue second quarter 2026 Y/Y Growth Comment
Perrigo Company Plc reported decrease in Revenue in the second quarter 2026 by -3.17% to $ 1,022.80 millions, from the same quarter in 2025. The decrease in the second quarter 2026 Perrigo Company Plc's Revenue compares unfavorably to the Company's average Revenue doubling of 9799.96%.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 143 other companies have achieved higher Revenue growth. While Perrigo Company Plc' s Revenue decline of -3.17% ranks overall at the positon no. 3032 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Perrigo Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
524352.11 %
9532.68 %
-99.98 %
(Dec 28 2013)
PRGO's II. Quarter Q/Q Revenue Comment
Perrigo Company Plc achieved in the II. Quarter 2026 below company average Revenue increase of 5.61% quarter on quarter, to $ 1,022.80 millions.
Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 1.25% growth in the II. Quarter a year ago
Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Perrigo Plc's Revenue growth quarter on quarter, overall rank is 1103.
Perrigo Company Plc achieved in the II. Quarter 2026 below company average Revenue increase of 5.61% quarter on quarter, to $ 1,022.80 millions.
II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 1.25% in the II. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Perrigo Plc's Revenue growth quarter on quarter, overall rank is 1103.
Perrigo Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 27 2026)
12 Months Ending (Mar 28 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 27 2025)
12 Months Ending (Jun 28 2025)
Cumulative Revenue 12 Months Ending
$ 4,144.00
$ 4,177.50
$ 4,252.30
$ 4,281.00
$ 4,325.30
Y / Y Revenue Growth (TTM)
-4.19 %
-3.6 %
-2.74 %
-2.5 %
-2.29 %
Year on Year Revenue Growth Overall
Ranking
# 2826
# 2563
# 1793
# 1230
# 1070
Seqeuential Revenue Change (TTM)
-0.8 %
-1.76 %
-0.67 %
-1.02 %
-0.19 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2632
# 2244
# 1566
# 1179
# 2208
Cumulative Revenue growth Comment
Perrigo Plc's cumulative 12 months Revenue continue to decrease, but on the faster rate at -4.19% year on year, at Jun 27 2026 compare to the -3.6% decrease at Mar 28 2026. If the Perrigo Plc's fiscal year would end at Jun 27 2026, annual Revenue would be $4,144 millions.
In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2563 to 2826.
Perrigo Plc's cumulative 12 months Revenue continue to decrease, but on the faster rate at -4.19% year on year, at Jun 27 2026 compare to the -3.6% decrease at Mar 28 2026. If the Perrigo Plc's fiscal year would end at Jun 27 2026, annual Revenue would be $4,144 millions.
In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2563 to 2826.
About Perrigo Plc Revenue Growth Rates (PRGO), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
